RxDoctor Payments Data

Melissa Miranda

Nurse Practitioner · Wesley Chapel, FLNPI 1235648882

Payments from drug & device makers

$15,271in general payments, 2019–2025

Across 810 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Pfizer$986
  • Neurocrine Biosciences, Inc.$762
  • Amgen$727
  • Teva Pharmaceuticals USA, Inc.$691
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$15,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)170$3,178
UCB, Inc.68$1,534
Pfizer57$986
Neurocrine Biosciences, Inc.42$762
Amgen(2 entities)51$727
Teva Pharmaceuticals USA, Inc.58$691
Biohaven Pharmaceutical Holding Company Ltd.40$584
Lundbeck LLC22$531
Lilly USA, LLC22$385
Jazz Pharmaceuticals Inc.13$372
Upsher-smith Laboratories LLC16$359
SK Life Science, Inc.9$303
Novartis22$301
Amneal Pharmaceuticals LLC14$281
Eisai Inc.12$278
MDD US Operations, LLC18$269
Impel Pharmaceuticals Inc.14$260
Otsuka America Pharmaceutical, Inc.12$240
Biohaven Pharmaceuticals, Inc.19$225
Acadia Pharmaceuticals Inc8$176
Sumitomo Pharma America, Inc.10$165
Avanir Pharmaceuticals, Inc.6$164
Takeda Pharmaceuticals U.S.A., Inc.6$154
Catalyst Pharmaceuticals, Inc.6$141
Johnson & Johnson(2 entities)6$140
Scilex Pharmaceuticals Inc.6$139
Seagen Inc.1$125
Boston Scientific4$119
CSL Behring6$115
Kyowa Kirin, Inc.7$110
Acorda Therapeutics, Inc5$108
Argenx US, Inc.4$102
Biogen5$101
Axsome Therapeutics, Inc.4$101
Intuitive Surgical1$98
AstraZeneca4$97
Bristol Myers Squibb4$89
Neurelis, Inc.5$88
Sunovion Pharmaceuticals Inc.5$83
Averitas Pharma Inc.3$80
Mallinckrodt Hospital Products Inc.3$55
Impel Pharmaceuticals LLC2$49
Aucta Pharmaceuticals, Inc.3$46
Harmony Biosciences LLC1$43
Arbor Pharmaceuticals, Inc.2$41
Sanofi2$40
Merz Pharmaceuticals, LLC2$38
Supernus Pharmaceuticals, Inc.2$36
Tanabe Pharma America, Inc.1$35
Currax Pharmaceuticals LLC2$28
Almatica Pharma LLC1$25
Avadel CNS Pharmaceuticals, LLC1$21
Banner Life Sciences, LLC1$20
Collegium Pharmaceutical, Inc.1$16
Avion Pharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,271 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$82,578
Medicare patients
261
Services billed
7,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$251,500
Emgality PenGalcanezumab-Gnlm185$150,408
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5016$131,758
BotoxOnabotulinumtoxina94$121,102
QuliptaAtogepant94$120,445
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5036$93,096
UbrelvyUbrogepant56$82,618
Nurtec OdtRimegepant Sulfate67$81,331
Aimovig AutoinjectorErenumab-Aooe71$79,986
NeuproRotigotine23$32,760
VimpatLacosamide16$22,412
Emgality SyringeGalcanezumab-Gnlm14$18,414
FycompaPerampanel15$18,268
ZavzpretZavegepant Hcl11$12,169
Memantine Hcl218$5,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$3,178$324,165244 claims
Neurocrine Biosciences, Inc.Ingrezza$762$251,50029 claims
CSL BehringPrivigen$115$131,75816 claims
PfizerNurtec Odt, Zavzpret$986$93,50078 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$154$93,09636 claims
UCB, Inc.Neupro, Vimpat$1,534$55,17239 claims
Eisai Inc.Fycompa$278$18,26815 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$281$1,54114 claims
Upsher-smith Laboratories LLCTopiramate$359$1,269114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →